Lymphadenopathy medical therapy: Difference between revisions
No edit summary |
|||
(9 intermediate revisions by 6 users not shown) | |||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The optimal therapy for [[lymphadenopathy]] depends on the underlying cause. [[Antimicrobial]] therapy is administered for infections. [[Chemotherapy]] is instituted for those tumors that cannot be treated by surgery. [[Radiation]] therapy is indicated in refractory tumors and [[metastatic]] tumors. | |||
==Principles of Therapy== | ==Principles of Therapy== | ||
Medical management of lymphadenopathy depends on the underlying cause. | Medical management of lymphadenopathy depends on the underlying cause. | ||
* Antibiotics, antivirals, antifungals and antiparasitic medications are prescribed for infections due to bacteria, virus, fungi and parasites respectively. | * [[Antibiotics]], [[antivirals]], [[antifungals]], and [[antiparasitic]] medications are prescribed for infections due to [[bacteria]], [[virus]], [[fungi]], and [[parasites]] respectively. | ||
* [[Chemotherapy]] is instituted for those tumors that cannot be treated by surgery. | * [[Chemotherapy]] is instituted for those tumors that cannot be treated by surgery. | ||
* [[Radiation therapy]] is used in refractory tumors and metastatic tumors. | * [[Radiation therapy]] is used in refractory tumors and [[metastatic]] [[tumors]].<ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |year=2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref> | ||
==Therapy Based on Clinical Form== | ==Therapy Based on Clinical Form== | ||
Line 167: | Line 169: | ||
</div> | </div> | ||
<div class="mw-customtoggle-table20" style="cursor: pointer; border-radius: 0 0 | <div class="mw-customtoggle-table20" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Wuchereria Bancrofti''' | ▸ '''Wuchereria Bancrofti''' | ||
</font> | </font> | ||
</div> | </div> | ||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Mycobacterium Tuberculosis}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Intensive Phase †''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Isoniazid]] 10 mg/kg PO 3 times per week''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 25 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Pyrazinamide]] 35 mg/kg PO 3 times per week''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ethambutol]] 14.5-21.1 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Ethambutol]] 36.4-52.6 mg/kg PO 3 times per week'''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Continuation Phase ††''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Isoniazid]] 10 mg/kg PO 3 times per week × 2 months''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO qd'''''<BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week × 2 months''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>†</sup> For 2 months <br><sup>††</sup> For 4 months<br>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book | last1 = | first1 = | last2 = | first2 = | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages = }}</ref> </SMALL> | |||
|- | |||
|} | |||
|} | |||
|} | |||
===Regional Lymphadenitis=== | ===Regional Lymphadenitis=== | ||
Line 425: | Line 465: | ||
</div> | </div> | ||
<div class="mw-customtoggle-table49" style="cursor: pointer; border-radius: 0 0 | <div class="mw-customtoggle-table49" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Leishmania''' | ▸ '''Leishmania''' | ||
Line 465: | Line 505: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>†</sup> For 2 months <br><sup>††</sup> For 4 months<br>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book | last1 = | first1 = | last2 = | first2 = | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages = }}</ref> </SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>†</sup> For 2 months <br><sup>††</sup> For 4 months<br>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book | last1 = | first1 = | last2 = | first2 = | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages = }}</ref> </SMALL> | ||
|- | |- | ||
|} | |||
|} | |} | ||
|} | |} | ||
Line 475: | Line 516: | ||
{{WS}} | {{WS}} | ||
[[Category:Inflammations]] | [[Category:Inflammations]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Physical examination]] | [[Category:Physical examination]] |
Latest revision as of 20:50, 29 January 2021
Lymphadenopathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphadenopathy medical therapy On the Web |
American Roentgen Ray Society Images of Lymphadenopathy medical therapy |
Risk calculators and risk factors for Lymphadenopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Vendhan Ramanujam M.B.B.S [3]
Overview
The optimal therapy for lymphadenopathy depends on the underlying cause. Antimicrobial therapy is administered for infections. Chemotherapy is instituted for those tumors that cannot be treated by surgery. Radiation therapy is indicated in refractory tumors and metastatic tumors.
Principles of Therapy
Medical management of lymphadenopathy depends on the underlying cause.
- Antibiotics, antivirals, antifungals, and antiparasitic medications are prescribed for infections due to bacteria, virus, fungi, and parasites respectively.
- Chemotherapy is instituted for those tumors that cannot be treated by surgery.
- Radiation therapy is used in refractory tumors and metastatic tumors.[1]
Therapy Based on Clinical Form
Generalized Lymphadenitis
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Mycobacterium Tuberculosis ▸ Brucella ▸ Leptospira ▸ Treponema pallidum ▸ Burkholderia ▸ Salmonella Typhi Chlamydia ▸ Chlamydia Trachomatis Fungi ▸ Histoplasma ▸ Cryptococcus Neoformans Viral ▸ Measles Virus ▸ Rubella Virus ▸ Epstein-Barr Virus ▸ Cytomegalovirus ▸ Herpes Simplex Virus ▸ Human Immunodeficiency Virus Protozoans ▸ Leishmania ▸ Trypanosoma ▸ Toxoplasma Gondii Helminths ▸ Brugia Malayi ▸ Wuchereria Bancrofti |
|
Regional Lymphadenitis
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.
Cervical Lymphadentitis - Bacteria ▸ Group A Beta-Hemolytic Streptococci ▸ Staphylococcus Aureus ▸ Mycobacterium Tuberculosis ▸ Mycobacterium Scrofulaceum ▸ Mycobacterium Avium-Intracellulare ▸ Bartonella Henselae ▸ Francisella Tularensis
|